12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Elvitegravir regulatory update

Gilead submitted an NDA to FDA for elvitegravir to treat HIV-1 infection in treatment-experienced adults. Last month, EMA accepted for...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >